Compare ThredUp Inc (TDUP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ThredUp Inc vs State Street SPDR S&P Biotech ETF — how do they compare? ThredUp Inc trades at $3.17 (market cap $405.82M), while State Street SPDR S&P Biotech ETF trades at $156.9. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| TDUP | XBI | |
|---|---|---|
Market Cap | $405.82M | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $12.08 | $164.28 |
52-Week Low | $3.08 | $88.79 |
Enterprise Value | $404.00M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.
The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.
XBI trades at $159.39, up 0.84% today, with a bullish technical signal from moving averages and a strong 80.2% 1-year return. The ETF holds 155 biotech stocks, benefiting from recent M&A and AI-driven drug discovery trends. Analyst coverage is limited to one hold rating, while institutional interest is evident with Bay Colony Advisors adding a $793,000 position in Q2 2026.
Outlook remains positive due to sector momentum, but risks include high volatility and policy uncertainty. The equal-weight strategy offers upside in bullish cycles, yet investors face elevated drawdowns compared to broader healthcare ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
